Literature DB >> 26416931

Diagnosis and Management of Infantile Hemangioma.

David H Darrow, Arin K Greene, Anthony J Mancini, Amy J Nopper.   

Abstract

Infantile hemangiomas (IHs) are the most common tumors of childhood. Unlike other tumors, they have the unique ability to involute after proliferation, often leading primary care providers to assume they will resolve without intervention or consequence. Unfortunately, a subset of IHs rapidly develop complications, resulting in pain, functional impairment, or permanent disfigurement. As a result, the primary clinician has the task of determining which lesions require early consultation with a specialist. Although several recent reviews have been published, this clinical report is the first based on input from individuals representing the many specialties involved in the treatment of IH. Its purpose is to update the pediatric community regarding recent discoveries in IH pathogenesis, treatment, and clinical associations and to provide a basis for clinical decision-making in the management of IH.
Copyright © 2015 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26416931     DOI: 10.1542/peds.2015-2485

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  50 in total

1.  M1 Macrophage-Induced Endothelial-to-Mesenchymal Transition Promotes Infantile Hemangioma Regression.

Authors:  Keith Q Wu; Christopher S Muratore; Eui-Young So; Changqi Sun; Patrycja M Dubielecka; Anthony M Reginato; Olin D Liang
Journal:  Am J Pathol       Date:  2017-07-12       Impact factor: 4.307

Review 2.  Advances in the Medical Management of Vascular Anomalies.

Authors:  Kiersten W Ricci
Journal:  Semin Intervent Radiol       Date:  2017-09-11       Impact factor: 1.513

Review 3.  Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies.

Authors:  Hao Yang; Dong-Lai Hu; Qiang Shu; Xiao-Dong Guo
Journal:  World J Pediatr       Date:  2019-07-24       Impact factor: 2.764

Review 4.  A Basic Introduction to Pediatric Vascular Anomalies.

Authors:  Sarah N Eberson; Sudhen B Desai; Denise Metry
Journal:  Semin Intervent Radiol       Date:  2019-05-22       Impact factor: 1.513

5.  Postdiagnostic use of β-blockers and other antihypertensive drugs and the risk of recurrence and mortality in head and neck cancer patients: an observational study of 10,414 person-years of follow-up.

Authors:  S-A Kim; H Moon; J-L Roh; S-B Kim; S-H Choi; S Y Nam; S Y Kim
Journal:  Clin Transl Oncol       Date:  2017-01-16       Impact factor: 3.405

6.  Transfection of adenovirus-mediated mircoRNA-126 gene into infant hemangioma endothelial cells in vitro.

Authors:  Zhe Cao; Yong-Qiang Guo; Sheng-Jian Tang; Shen-Xing Tan; Chang-Ying Niu; Chun-Lei Miao; Wei Zhang; Yu-Li Li; Long Zhang; Jing-Han Wang; Xiao-Qin Liang
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

7.  How to Manage Disfiguring Scars in Involuted Infantile Hemangioma.

Authors:  Shunsuke Yuzuriha; Fumio Nagai; Masahiko Noguchi
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-06-06       Impact factor: 4.730

8.  Assessment of Infantile Hemangiomas Using a Handheld Wireless Diffuse Optical Spectroscopic Device.

Authors:  Christopher J Fong; Maria C Garzon; Jennifer W Hoi; Hyun K Kim; Christine T Lauren; Kimberly Morel; Lauren Geller; Nina Antonov; Nicole Weitz; June Wu; Andreas H Hielscher
Journal:  Pediatr Dermatol       Date:  2017-05-26       Impact factor: 1.588

9.  Infantile hemangioma: factors causing recurrence after propranolol treatment.

Authors:  Lei Chang; Dongze Lv; Zhang Yu; Gang Ma; Hanru Ying; Yajing Qiu; Yifei Gu; Yunbo Jin; Hui Chen; Xiaoxi Lin
Journal:  Pediatr Res       Date:  2017-10-11       Impact factor: 3.756

Review 10.  Classification of congenital nasal deformities: a proposal to amend the existing classification.

Authors:  Marta Fijałkowska; Bogusław Antoszewski
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-07-06       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.